title: [Prophylaxis of toxic effects on the peripheral venous system associated with intravenous administration of vinorelbine].
abstract: Vinorelbine is effective in the treatment of a number of malignancies. However, beside the haematologic and not haematologic toxicity as thrombocytopenia, granulocytopenia, fatigue, paresthesias, nausea and vomiting, one of the most common side effects is the local irritation with thrombophlebitis. The side effect, reported in about 10-26% of patients receiving vinorelbine infusions, is due to the vescicant and irritant action of the drug. Many studies have been performed in order to reduce the incidence of venous irritation either with concomitant administration of anti-inflammatory drugs as defibrotide or ketorolac, or changing infusion schedule from bolus infusion to a 20-30 minute infusion. Aim of this review is to define peripheral venous system toxicity of vinorelbine and the best way of administration.
authors.affiliation: Divisione di Oncologia Medica, Istituto Europeo di Oncologia, IRCCS, Milano, Italia.
authors.forename: S
authors.initials: S
authors.lastname: Cinieri
authors.forename: L
authors.initials: L
authors.lastname: Orlando
authors.forename: E
authors.initials: E
authors.lastname: Cocorocchio
authors.forename: E
authors.initials: E
authors.lastname: Munzone
authors.forename: C
authors.initials: C
authors.lastname: Catania
authors.forename: C
authors.initials: C
authors.lastname: Brunetti
authors.forename: A
authors.initials: A
authors.lastname: Rocca
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: F
authors.initials: F
authors.lastname: Nolè
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000627:therapeutic use; D007262:Infusions, Intravenous; D020910:Ketorolac / Q000008:administration & dosage / Q000627:therapeutic use; D010689:Phlebitis / Q000139:chemically induced* / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011089:Polydeoxyribonucleotides / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D014680:Veins / Q000187:drug effects*; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000972:Antineoplastic Agents, Phytogenic; D010975:Platelet Aggregation Inhibitors; D011089:Polydeoxyribonucleotides; C036901:defibrotide; D014747:Vinblastine; D003907:Dexamethasone; D000077235:Vinorelbine; D006854:Hydrocortisone; D020910:Ketorolac